Is West Pharmaceutical Services profitable in 2026?

Yes. Q2 2026 net sales reached $872.3 million, up 13.8% year-over-year, with adjusted EPS of $2.37, up about 29% year-over-year, as of July 23, 2026. Full-year 2026 guidance was raised to $3.345-3.380 billion in net sales and $8.85-9.05 adjusted EPS.

Could AI replace West Pharmaceutical Services?

Unlikely. West's revenue depends on FDA/EMA-regulated drug-contact elastomer and syringe components locked into approved drug filings, which requires costly re-validation to switch. As of January 2026 West uses AI mainly for internal vision-inspection and manufacturing efficiency, not as a substitute for physical regulated production.

Who is West Pharmaceutical Services' biggest competitor?

Closest specialized rivals are Stevanato Group, SCHOTT Pharma, Datwyler, and Gerresheimer, per a March 17, 2026 market analysis. None has dislodged West's incumbency; West reported a win rate exceeding 90% on new biologics molecule launches as of July 23, 2026, per company statements.

Who owns West Pharmaceutical Services?

West is an independent publicly traded company, NYSE ticker WST, and a member of the S&P 500 as of July 23, 2026. It has no parent company. Market capitalization was approximately $25.0-25.2 billion as of July 24, 2026, per gurufocus.com.

Did West Pharmaceutical Services have layoffs in 2026?

No layoffs are reported. Company press releases cite over 10,000 team members globally as of July 23, 2026, and third-party data provider Revelio Labs estimated total headcount at about 13,416 as of December 2025, up 8.2% from 2023, indicating growth rather than cuts.

What happened in West Pharmaceutical Services' 2026 cyberattack?

A ransomware-style intrusion on May 4, 2026 forced a temporary global operations shutdown. Palo Alto Networks Unit 42 confirmed full containment on May 27, 2026. The incident modestly dampened the West Vantage contract-manufacturing segment, which grew only 0.8% organically in Q2 2026.

Biotech tools companies · United States

West Pharmaceutical Services

westpharma.com ↗

Makes elastomer stoppers, syringes, and containment systems that seal injectable drugs.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from August 31, 2026 · Every call on the record Checkpoint: CEO transition from Eric Green to Michel Lagarde completes

The call

West sits inside drug filings that pharma companies won't risk re-validating, and its next real test is a CEO handover, not a rival's product.

West Pharmaceutical makes rubber stoppers, syringes, and other containers that hold medicines and vaccines. Once a drug company gets FDA approval with West's parts inside, switching to a rival like Stevanato means re-testing everything from scratch, which costs millions and delays launches, so drug makers almost never do it. The one thing that could trip up this setup is whether the new CEO starting September 2026 keeps the same focus on customers and spending discipline that built this position, plus whether a ransomware attack from May 2026 causes hidden legal or customer problems down the road.

Why

AI pressure: None apparent. AI models can't replace physical validated components inside a regulated drug filing, so this is a manufacturing business, not a software one. Could AI do the core job? Unlikely.

Bigger players: Stevanato Group, SCHOTT Pharma, Datwyler, Gerresheimer. Rivals make similar stoppers and syringes, but West already wins over 90% of new biologics molecule launches specified into filings. Could a giant copy it? No, they are blocked.

What protects it. Once a pharma company's FDA or EMA filing names West's component, swapping suppliers means costly re-validation nobody wants to redo.

What would change this call

West's new-molecule win rate reported in quarterly filings drops from >90% into the 60s-70s. Would show rivals like Stevanato or SCHOTT Pharma are displacing West on new biologics specs.
CEO transition to Michel Lagarde completes August 31, 2026 without disruption to Q3/Q4 guidance. Would show leadership handover is not eroding customer or revenue momentum.
H2 2026 disclosures on the May 2026 ransomware incident show litigation or prolonged West Vantage revenue drag. Would show the cyberattack caused lasting customer or operational damage rather than a contained event.

Key numbers

Q2 2026 net sales $872.3M, up 13.8% y/y (2026-07-23)
>90% win rate on new biologics molecule launches (2026-07-23)
~800 active Annex 1 sterile-manufacturing upgrade projects (2026-07-23)

Named risks

Residual fallout from May 2026 cyberattack including possible litigation or data-breach disclosures in H2 2026. Severity: medium
CEO transition execution risk as Eric Green retires August 31, 2026 and Michel Lagarde takes over. Severity: medium
West Vantage contract-manufacturing segment growth remains muted (0.8% organic in Q2 2026) post-cyberattack. Severity: low
Shares trading near 52-week highs (~$387 intraday July 23, 2026) raise valuation reversal risk on any earnings miss. Severity: low
Headcount and employee data inconsistencies across sources create uncertainty in workforce scale reporting. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Stevanato Group	contesting	Same-niche elastomer/syringe specialist competing for biologics contracts, as of 2026-03-17
SCHOTT Pharma	contesting	Named among closest pharma-packaging rivals in industry analysis, 2026-03-17
Datwyler Holding	contesting	Elastomer component competitor in same regulated niche, per 2026-03-17 analysis
Gerresheimer AG	contesting	Estimated ~2% healthcare packaging share, comparable to West's ~2%, as of 2026-07-11
Becton Dickinson	contesting	Larger adjacent player with $21.8B FY2025 sales in syringes/infusion systems
Amcor	contesting	Merged with Berry Global April 2025 forming ~$23B packaging company, overlapping segments

Questions people ask

Is West Pharmaceutical Services profitable in 2026?: Yes. Q2 2026 net sales reached $872.3 million, up 13.8% year-over-year, with adjusted EPS of $2.37, up about 29% year-over-year, as of July 23, 2026. Full-year 2026 guidance was raised to $3.345-3.380 billion in net sales and $8.85-9.05 adjusted EPS.
Could AI replace West Pharmaceutical Services?: Unlikely. West's revenue depends on FDA/EMA-regulated drug-contact elastomer and syringe components locked into approved drug filings, which requires costly re-validation to switch. As of January 2026 West uses AI mainly for internal vision-inspection and manufacturing efficiency, not as a substitute for physical regulated production.
Who is West Pharmaceutical Services' biggest competitor?: Closest specialized rivals are Stevanato Group, SCHOTT Pharma, Datwyler, and Gerresheimer, per a March 17, 2026 market analysis. None has dislodged West's incumbency; West reported a win rate exceeding 90% on new biologics molecule launches as of July 23, 2026, per company statements.
Who owns West Pharmaceutical Services?: West is an independent publicly traded company, NYSE ticker WST, and a member of the S&P 500 as of July 23, 2026. It has no parent company. Market capitalization was approximately $25.0-25.2 billion as of July 24, 2026, per gurufocus.com.
Did West Pharmaceutical Services have layoffs in 2026?: No layoffs are reported. Company press releases cite over 10,000 team members globally as of July 23, 2026, and third-party data provider Revelio Labs estimated total headcount at about 13,416 as of December 2025, up 8.2% from 2023, indicating growth rather than cuts.
What happened in West Pharmaceutical Services' 2026 cyberattack?: A ransomware-style intrusion on May 4, 2026 forced a temporary global operations shutdown. Palo Alto Networks Unit 42 confirmed full containment on May 27, 2026. The incident modestly dampened the West Vantage contract-manufacturing segment, which grew only 0.8% organically in Q2 2026.

Timeline

2026-07-23Q2 2026 results: net sales $872.3M (+13.8% y/y), adjusted EPS $2.37 (+29% y/y), FY guidance raised
2026-07-01Completed $112.5M sale of SmartDose 3.5mL on-body device and facilities to AbbVie
2026-06-01Announced Michel Lagarde as next President/CEO, succeeding retiring Eric Green
2026-05-27Palo Alto Networks Unit 42 confirmed full containment of May cyberattack
2026-05-04Ransomware-style cyberattack forced temporary global operations shutdown
2026-04-09Rebranded contract manufacturing division as West Vantage
2026-02-12Reported FY2025 net sales of $3.07 billion
2026-01-01SmartDose 3.5mL sale to AbbVie announced

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE